Literature DB >> 24037455

Drug-induced liver injury after allogeneic bone marrow transplantation.

Takayoshi Tachibana1, Akito Nozaki, Makiko Enaka, Eri Yamamoto, Rika Kawasaki, Hideyuki Koharazawa, Maki Hagihara, Daisuke Ishibashi, Yuki Nakajima, Hideyuki Kuwabara, Naoto Tomita, Yoshiaki Ishigatsubo, Shin Fujisawa.   

Abstract

A 23-year-old woman developed acute severe hepatitis and jaundice on day 183 after bone marrow transplantation from HLA-B antigen mismatched-related donor. The administration of prednisolone and cessation of the prescribed drugs resolved the liver injury. Drug lymphocyte stimulation test was positive for acyclovir, and liver biopsy indicated the characteristics of drug-induced liver injury (DILI) rather than graft-versus-host disease. Physicians should keep DILI in mind when considering differential diagnosis for liver complications after allogeneic cell transplantation.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24037455     DOI： 10.1007/s12185-013-1434-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  21 in total

Review 1.  Biomarkers for the diagnosis and management of drug-induced liver injury.

Authors:  Paul B Watkins
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115

2.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

Authors:  George B McDonald; John T Slattery; Michelle E Bouvier; Song Ren; Ami L Batchelder; Thomas F Kalhorn; H Gary Schoch; Claudio Anasetti; Ted Gooley
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

Review 3.  Case definition and phenotype standardization in drug-induced liver injury.

Authors:  G P Aithal; P B Watkins; R J Andrade; D Larrey; M Molokhia; H Takikawa; C M Hunt; R A Wilke; M Avigan; N Kaplowitz; E Bjornsson; A K Daly
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

4.  Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.

Authors:  Eiji Kusumi; Masahiro Kami; Yoshinobu Kanda; Naoko Murashige; Kunihiko Seki; Masayo Fujiwara; Rikako Koyama; Tsunehiko Komatsu; Akiko Hori; Yuji Tanaka; Koichiro Yuji; Tomoko Matsumura; Kazuhiro Masuoka; Atsushi Wake; Shigesaburo Miyakoshi; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

5.  Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.

Authors:  I Amigues; N Cohen; D Chung; S K Seo; C Plescia; A Jakubowski; J Barker; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-09       Impact factor: 5.742

6.  Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.

Authors:  M García-Cortés; M I Lucena; K Pachkoria; Y Borraz; R Hidalgo; R J Andrade
Journal:  Aliment Pharmacol Ther       Date:  2008-02-18       Impact factor: 8.171

7.  Histopathology of graft versus host disease of the liver.

Authors:  A Quaglia; R Duarte; D Patch; K Ngianga-Bakwin; A P Dhillon
Journal:  Histopathology       Date:  2007-05       Impact factor: 5.087

8.  Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.

Authors:  Eray Goekkurt; Jan Stoehlmacher; Christian Stueber; Christine Wolschke; Thomas Eiermann; Simona Iacobelli; Axel R Zander; Gerhard Ehninger; Nicolaus Kröger
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

9.  Chronic graft-versus-host disease of the liver presenting as an acute hepatitis following nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Hoyoung Maeng; Jae-Hyun Lee; June Won Cheong; Seung Tae Lee; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

10.  Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality.

Authors:  Jeannine S McCune; Ami Batchelder; H Joachim Deeg; Ted Gooley; Scott Cole; Brian Phillips; H Gary Schoch; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2007-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.